drugset / Trial / NCT01490229

Ezetimibe Versus Nutraceuticals in Statin-intolerant Patients

NCT01490229

Phase 4 Unknown 100 enrolled University of Roma La Sapienza
RandomizedParallel-groupSingle-blindTreatment

Summary

Pharmacologic alternatives in statin-intolerant patients include ezetimibe and nutraceuticals (i.e. compounds derived from foods with cholesterol lowering actions). The investigators will compare the efficacy and tolerability of ezetimibe versus a nutraceutical-based protocol in statin-intolerant patients treated with percutaneous coronary intervention.

Timeline

Start
2013-01
Primary completion
2014-12
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Berberine Traditional medicine (herbal / TCM) 500 mg Oral
Comparator Ezetimibe Unknown 10 mg Oral
Subject Policosanol Small molecule 10 mg Oral
Subject red yeast rice Traditional medicine (herbal / TCM) 200 mg Oral